We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+2.79%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$511M
AUM Growth
+$1.51M
Cap. Flow
-$202K
Cap. Flow %
-0.04%
Top 10 Hldgs %
52.15%
Holding
56
New
12
Increased
14
Reduced
11
Closed
16

Top Buys

Rank Stock Value
1
ZURA icon
Zura Bio
ZURA
+$26.5M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$15.9M
3
ALKS icon
Alkermes
ALKS
+$12.5M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$12.2M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$8.38M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$21.9M
2
TVTX icon
Travere Therapeutics
TVTX
+$17.2M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$16.9M
4
KALV
KalVista Pharmaceuticals
KALV
+$12.6M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
URGN icon
51
UroGen Pharma
URGN
$1.86B
– –
-39,222
Closed -$362K
VKTX icon
52
PUT
Viking Therapeutics
VKTX
$3.7B
– –
-80,000
Closed -$1.33M
ZVRA icon
53
Zevra Therapeutics
ZVRA
$562M
– –
-347,824
Closed -$1.91M
ITCI
54
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-70,371
Closed -$3.81M
CBAY
55
DELISTED
Cymabay Therapeutics
CBAY
– –
-507,500
Closed -$4.43M
ISEE
56
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-694,009
Closed -$16.9M
1 2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Great Point Partners held 56 positions worth $511M, up 0.3% from $509M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Great Point Partners's Q2 2023 filing shows 12 new, 14 increased, 11 reduced and 16 closed positions. Its largest new stake was Zura Bio: 3,295,000 shares worth $27M. The largest sale was Jazz Pharmaceuticals, an estimated $21.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

  • Great Point Partners's largest Q2 2023 buy was Zura Bio: 3,295,000 shares worth $27M.
  • Great Point Partners added most to Rhythm Pharmaceuticals in Q2 2023, an estimated $12.2M increase.
  • Great Point Partners's biggest Q2 2023 reduction was Travere Therapeutics, cutting an estimated $17.2M.
  • Great Point Partners fully exited Jazz Pharmaceuticals in Q2 2023, selling an estimated $21.9M.
  • Great Point Partners's ten largest holdings make up 52% of its $511M portfolio in Q2 2023.
  • Great Point Partners opened 12 new positions and closed 16 in Q2 2023.
  • Great Point Partners's portfolio value rose 0.3% quarter-over-quarter to $511M.

Based on Great Point Partners's 13F filing for Q2 2023, filed 14 Aug 2023.